Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In an international, double-blind study in 82 patients aged 2 to 17, the incidence of drug-related AEs was 48%
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury